Previous close | 0.2600 |
Open | N/A |
Bid | 0.0000 |
Ask | 1.2000 |
Strike | 3.50 |
Expiry date | 2024-06-28 |
Day's range | 0.2600 - 0.2600 |
Contract range | N/A |
Volume | |
Open interest | 1 |
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive O
Strengthening Operational Efficiency and Execution towards Sustainable Accessibility for Diverse Populations within Global Healthcare SystemsNEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schiz
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...